Industry News

Cell MedX Corp., a development stage company focused on the commercialization of therapeutic devices for patients living with diseases such as diabetes, is pleased to announce that on September 26, 2016 the Company cancelled options to acquire up to 17,500,000 common shares of the Company, at an initial price of $0.05 per share. The Cancelled Options represent the unvested portion of those options that were initially granted to Ms."/>
Cell MedX Corp. (CMXC) Cancels Options and Appoints a Director
Horizon Pharma plc, a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has entered into a rebate agreement with Prime Therapeutics, which secures formulary status for its primary care medicines. The rebate agreement begins on October 1, 2016.. “Our philosophy is and will..."/>
Horizon Pharma plc Provides Update on PBM Formulary Status for Primary Care Medicines
Cara Therapeutics, Inc., a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it will host an industry symposium titled“ Moving Beyond Mu with Kappa Opioid Receptor Agonists- Leaving the Baggage Behind” at the Orthopaedic Trauma Association 2016 Annual Meeting, which will be held October..."/>
Cara Therapeutics to Host Industry Symposium at the Orthopaedic Trauma Association 2016 Annual Meeting
Fibrocell Science, Inc., today announced that John Maslowski, Senior Vice President, Scientific Affairs of Fibrocell, will present at 9:15 am PDT on Thursday, October 6 at the annual Partnering Forum, part of the Cell& Gene Meeting on the Mesa to be held October 5-7 in La Jolla, California. A live webcast of Fibrocell’ s presentation will be available under the investor relations section of the company’ s website at, and also..."/>
Fibrocell to Present at 2016 Cell & Gene Meeting on the Mesa
CANTEL MEDICAL CORP. reported record US GAAP net income of $16,291,000, or $0.39 per diluted share, on an 18.3% increase in sales to a record $179,002,000 for the fourth quarter ended July 31, 2016. This compares with net income of $13,273,000, or $0.32 per diluted share, on sales of $151,255,000 for the fourth quarter ended July 31, 2015. For the full fiscal year ended July 31, 2016, the Company reported record US GAAP net income of..."/>
Cantel Medical Reports Record Results for the Fourth Quarter Ended July 31, 2016
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has successfully obtained provincial formulary coverage from the Ontario Drug Benefit Program for Pr Vistitan™. According to IMS data, over 80% of Ontario's glaucoma patient population rely on public medication coverage, who will now have improved access to this product. "This is a major milestone since the..."/>
Aequus Obtains Ontario Provincial Listing for Vistitan(TM)
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, and Sarepta Therapeutics, Inc., a commercial-stage developer of innovative RNA-targeted therapeutics, today announced a joint research collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy. The two companies will contribute their respective expertise to study an exon skipping treatment developed by Sarepta, together with an..."/>
Catabasis Pharmaceuticals and Sarepta Therapeutics Announce a Joint Research Collaboration in Duchenne Muscular Dystrophy
Chembio Diagnostics reported on Wednesday that it has been awarded a USD330, 000 contract from the US Centers for Disease Control and Prevention for POC surveillance diagnostic assays for Zika, Dengue and Chikungunya. Pursuant to the one year agreement, Chembio will provide its DPP Zika IgM/IgG Assay, DPP Zika/Chikungunya/Dengue IgM/IgG Combination Assay and DPP Micro Reader for a surveillance testing pilot programme in India, Peru, Guatemala and..."/>
Chembio wins USD330,000 CDC deal for Zika, Dengue and Chikungunya surveillance testing in India, Peru, Guatemala and Haiti
Biostage, Inc.,, a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, today announced that it will be presenting at the Cell& Gene Meeting on the Mesa being held October 5-7, 2016 in La Jolla, CA. Saverio La Francesca, MD, Executive VP and Chief Medical Officer of Biostage, will present on Thursday, October 6, 2016 at 3:15 p.m. PT."/>
Biostage to Present at the Cell & Gene Meeting on the Mesa
Amgen and Arrowhead Pharmaceuticals Inc. today announced two license and collaboration agreements to develop and commercialize RNA interference therapies for cardiovascular disease. These are the first programs to utilize Arrowhead's proprietary subcutaneous RNAi delivery platform. RNAi molecules may be designed to target and shut down specific gene products that contribute to various diseases."/>
Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations
Mirati Therapeutics, Inc. today announced the appointment of Dr. Carter to the Company's Board of Directors where he will also serve as a member of the Audit Committee and Compensation Committee, effective immediately. "It is a privilege to welcome such a respected and accomplished professional to our board of directors," said Charles M. Baum, M.D., Ph.D., president and CEO of Mirati."/>
Mirati Therapeutics Announces Appointment Of Dr. Bruce L.A. Carter To Board Of Directors
Cytokinetics, Inc. today announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the 2016 amendment to the License and Collaboration Agreement initially executed between Cytokinetics and Astellas Pharma Inc., in 2013 and amended in 2014. In July 2016, the companies expanded the collaboration related to the..."/>
Cytokinetics Announces Early Termination of Hart-Scott-Rodino Waiting Period for Expanded Collaboration With Astellas
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, today announced that preclinical data describing XPO1 inhibition with selinexor, the Company’ s lead, oral Selective Inhibitor of Nuclear Export/ SINE™ compound, in a..."/>
Karyopharm Publishes Preclinical Data in Nature Demonstrating Selinexor’s Potential in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
Genocea Biosciences, Inc., a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced positive results from its ongoing Phase 2 b trial evaluating a new Phase 3- ready formulation of GEN-003 for the treatment of genital herpes."/>
Genocea’s Genital Herpes Immunotherapy GEN-003 Demonstrates Significant Reduction of Viral Shedding in Phase 2b Clinical Trial
Otonomy, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, will host an Investor and Analyst Day on Friday, October 7, 2016, from 8:30 a.m. to 11:30 a.m. EDT in New York City. David A. Weber, Ph.D., president and chief executive officer, and other members of the Otonomy management team will provide an update of the OTIPRIO ® commercial launch and product..."/>
Otonomy to Host Investor and Analyst Day on October 7, 2016
Medtronic plc revealed on Wednesday the receipt of approval from the US Food and Drug Administration for the TrailBlazer angled support catheter for use in the peripheral vascular system for treating complex peripheral artery disease. With the US FDA approval, the company's TrailBlazer angled support catheter broadens its leading peripheral options and adds full spectrum of angled resources to meet provider needs. The company said the new..."/>
Medtronic awarded US FDA clearance of TrailBlazer angled peripheral support catheter for treating complex peripheral artery disease
Medtronic reported on Wednesday the receipt of the US Food and Drug Administration approval for its fully automated hybrid closed loop insulin delivery system MiniMed 670 G with most advanced SmartGuard HCL algorithm for people with Type 1 Diabetes 14 years of age and older. Through the company's SmartGuard HCL, the patients and providers can choose from increasing levels of automation that best fit their diabetes management needs. It is simplifying and..."/>
Medtronic passes US FDA approval for closed loop insulin delivery system MiniMed 670G with SmartGuard HCL algorithm for Type 1 Diabetes
Agilent Technologies' on Wednesday announced an agreement to develop cancer diagnostics in China based on Agilent Technologies' SureSelect target enrichment system. Agilent is a provider of target enrichment for next-generation DNA sequencing. Target enrichment saves researchers time and resources by enabling them to focus on regions of interest rather than looking at the entire genome."/>
Agilent Technologies enters into molecular diagnostics agreement with Burning Rock
Charles River Laboratories International reported on Wednesday that it has completed the acquisition of Agilux Laboratories for a purchase price of approximately USD64m in cash, subject to certain post-closing adjustments. Under the terms of an agreement, Agilux was acquired from a holding company controlled by its founders and Ampersand Capital Partners, its only institutional investor. Based in Worcester, Massachusetts, Agilux..."/>
Charles River Laboratories buys Agilux Laboratories for USD64m
Galena Biopharma, Inc., a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today announced that interim safety data from the Company’ s NeuVax™ Phase 2 b combination study will be presented at the upcoming European Society for Medical Oncology 2016 Congress in Copenhagen, Denmark. The clinical trial is a randomized, multicenter,..."/>
Galena Biopharma to Present NeuVax™ (nelipepimut-S) Interim Safety Data at the European Society for Medical Oncology (ESMO) 2016 Congress
Myriad Genetics, Inc. announced today that Chip Parkinson will join the company in the newly created position of executive vice president for Reimbursement Strategy. Parkinson will report to Mark C. Capone, president and CEO of Myriad Genetics with responsibility for facilitating additional global reimbursement for the Company’ s pioneering molecular diagnostic products. While personalized medicine offers tremendous promise to improve..."/>
Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy
Abeona Therapeutics Inc. a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that CEO& President, Timothy J. Miller, Ph.D., will be presenting for The Company at Cell Gene's Meeting on the Mesa in La Jolla, CA, October 5 th at 11:15 am PT. The following are the specific details regarding Abeona Therapeutics Presentation:. Event: Cell Gene Meeting on the Mesa..."/>
Abeona Therapeutics to Present at Cell Gene Meeting on the Mesa
TESARO retains right to co-market in China and receives option to license up to two novel immuno-oncology programs outside China WALTHAM, Mass., and SHANGHAI, China, Sept. 29, 2016-- TESARO, Inc., an oncology-focused biopharmaceutical company, and Zai Lab Co., Ltd., a biopharmaceutical company based in China, today announced a collaboration to support the development and commercialization of..."/>
TESARO and Zai Lab Announce Collaboration, Development and License Agreement
Community Health Systems, Inc. announced today that subsidiaries of the Company have signed a definitive agreement for the sale of four hospitals and their associated assets to subsidiaries of Curae Health, Inc. Facilities included in the transaction are 95- bed Merit Health Gilmore Memorial in Amory, Miss., 112- bed Merit Health Batesville in Batesville, Miss., 181- bed Merit Health Northwest Mississippi in Clarksdale, Miss. and 126- bed Highlands Regional..."/>
Community Health Systems Announces Definitive Agreement to Divest Four Rural Hospitals, Three in Mississippi, One in Florida
Inotek Pharmaceuticals Corporation, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that Timothy Barberich has been appointed to its Board of Directors. Barberich will serve as head of the Compensation Committee. Barberich founded Sepracor Inc., a publicly-traded, research-based pharmaceutical company, and served as Chairman and Chief..."/>
Inotek Pharmaceuticals Appoints Timothy Barberich to Board of Directors

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology766 Articles
Consumer Discretionary673 Articles
Financials530 Articles
Health Care435 Articles
Industrials432 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at